Autologous hematopoietic stem cell transplantation experience in patients with diffuse cutaneous systemic scleroderma

• Autores: Bazán-Ruiz, Susy, Aranda, Lourdes, Wong, Alfredo
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Repositorio: Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Lenguaje: español
• OAI Identifier: oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/1466
• Enlace del recurso: https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/1466
• Nivel de acceso: acceso abierto
• Materia: Esclerosis sistémica; Trasplante Autólogo; Movilización; Tratamiento; Systemic sclerosis; Autologous Transplantation; Mobilization; Treatment

Background: The progression and lack of therapeutic options leads to a large increase in morbidity and mortality in diffuse cutaneous systemic scleroderma. Clinical Case: Three patients with a diagnosis of rapidly progressing systemic scleroderma without severe cardiopulmonary or renal involvement with multiple lines of treatment including high doses of cyclophosphamide, submitted to autologous transplant (2015-2020) with conditioning based on Cyclophosphamide and Antithymocyte Globulin are presented as a therapeutic option. During the procedure, no various infectious infections were observed with a medullary seizure on day 10 and an average relapse of 9.6 months. Conclusions: Due to the good toxicity profile and good tolerance to the procedure, Autologous Transplantation should be considered as a treatment option in patients without high accumulated doses of cyclophosphamide or in early stages of disease.